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Abstract
A 49 year old gentleman presents with recurrent abdominal pain. The patient has a known history
of chronic pancreatitis, alcoholism and narcotic addiction. Work-up, including computed
tomography (CT) of the abdomen, demonstrated a 5.6 × 5.8 cm fluid collection contiguous with
the pancreas. This was not seen on CT 18 months earlier. The patient's pain did not improve with
bowel rest and pain control. He was transferred to another institution for endoscopic placement
of a transgastric pancreatic stent. The procedure decreased the size the cyst and the patient's pain
became more manageable.
Introduction
Pancreatic pseudocysts have been recognized for over 185
years [1]. Today most are alcohol related and more than
half are thought to resolve spontaneously [2]. This is a
case of a 49 year old gentleman who develops a pancreatic
pseudocyst that had to be surgically drained. Pancreatic
pseudocysts have a unique physiology that does not lend
itself easily to drainage [3]. Consequently management
has tended towards watchful waiting provided the cyst is
stable and asymptomatic [4]. Our patient also had nar-
cotic dependence. Some evidence suggests at least a phys-
iologic basis for the contribution of some narcotics
towards the development of a pancreatic pseudocyst [5-
7].
Case presentation
History of Present Illness
The patient was a 49 year old patient who presented with
abdominal pain. He had visited our emergency room 13
times in the last year and this would be his fourth admis-
sion. His abdominal pain was constant, mid-epigastric,
and exacerbated with eating. Why the pain flared up this
time was unclear. He did not consume any alcohol
recently or change his diet. He denied chest pain, short-
ness of breath, melena and fever. He had not vomited but
was nauseated.
Past Medical History
His only medical problem was chronic pancreatitis and its
complications. His pancreatitis was initially precipitated
by heavy alcohol use. In recent years he no longer drank
alcohol but was addicted to lortab. We were informed that
at one time he would take up to 30 or 40 pills a day of
lortab purchased illegally off the street.
Past Surgical History
None
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Past Social History
The patient smoked one pack per day. He no longer drank
alcohol. He was disability for chronic pancreatitis. He
denied drug use at this time, including non prescribed
narcotics.
Past Family History
His mother passed away from coronary artery disease. As
far as he knew, it did not develop when she was young.
Medications
His narcotic use varies. Presently he was taking lortab 5/
500 mg, four tablets a day. He also took Viokase-8 tablets,
four before meals and two before snacks.
Physical Exam
Vital signs: Afebrile. Pulse 77. Respiratory rate 18. Blood
pressure 135/73. Oxygen saturation 100% on room air.
In general he seemed uncomfortable. He sat still and
winced when he talked. Head exam: Normal cephalic,
atraumatic. Ears and throat were normal. He had poor
dentition although he still has his own teeth. Neck: I did
not note lymphadenopathy or a carotid murmur. Heart:
regular rate and rhythm. No murmur was noted. Lung
exam: clear with good air movement. Abdomen: Tender-
ness with palpation in the epigastric region. There was no
guarding or rebound tenderness. His abdomen was not
rigid. Bowel sounds were quiet. Extremities: no edema
and no clubbing of nails.
Laboratory
His amylase was elevated at 239 IU/L. White cell count
was 10.4 × 103/uL with 76% neutrophils. Hemoglobin
was 14.6 g/dL. His metabolic panel was normal. Calcium
was 8.7 mg/dL and his an albumin was 3.4 g/dL. His trig-
lycerides were 128 mg/dL. His alcohol level was 0.
Computed tomography (CT) with contrast of the abdo-
men and pelvis (figure 1) showed a large 5.6 × 5.8 cm low
attenuation collection with a well-defined wall contigu-
ous with the body of the pancreas. Mild fat stranding was
also noted around the pancreatic tail.
A CT of the abdomen 18 months earlier (figure 2) demon-
strated no pseudocyst or pancreatic inflammation.
Hospital course
The patient was admitted for bowel rest and pain control.
Because of continued abdominal pain, several days passed
and he still was unable to tolerate oral intake. Total
parenteral nutrition was provided. Follow up CT scans of
the abdomen on hospital days 7 and 14 showed no
change.
Finally, on hospital day 24 he was transferred to another
institution for pseudocyst drainage and stent placement.
He underwent transgastric endoscopic ultrasound and
CT of the abdomen showing a large 5.6 × 5.8 cm fluid collec- tion contiguous with the body of the pancreas Figure 1
CT of the abdomen showing a large 5.6 × 5.8 cm fluid 
collection contiguous with the body of the pancreas.
CT of the abdomen of the same patient 18 months earlier Figure 2
CT of the abdomen of the same patient 18 months 
earlier. No pancreatic fluid collection is seen.Cases Journal 2008, 1:219 http://www.casesjournal.com/content/1/1/219
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fluoroscopy guided pseudocyst drainage with stent place-
ment.
Outcome
The patient's pain improved following stent placement.
Following discharge, the patient continued to have peri-
odic admissions for flare ups of abdominal pain, but they
became less frequent. Figure 3 shows a CT of the patient's
abdomen seven months later. The pseudocyst measures
17 mm in size with the stent still in place. The patient was
also enrolled in a methadone program to address his nar-
cotic addiction.
About two years after this admission the patient expired.
He died at his home suddenly. Autopsy reports concluded
cause of death to be a drug overdose, methadone and
hydrocodone. It also noted severe atherosclerosis of the
coronary arteries.
Discussion
Pancreatic pseudocysts develop after acute pancreatitis 5
to 15% of the time, and more than half are thought to
resolve spontaneously. Most (~65%) are alcohol related
[2]. While true cysts have an epithelial lining that secretes
the cystic fluid, pancreatic pseudocysts are filled with exo-
crine secretions from a disruption of its own ductal sys-
tem. The body reacts to the hostile, digestive enzymes-
amylase, lipase and others, with inflammation. A fibrous
wall forms over several weeks to contain the spill and pro-
tect the surrounding tissue [2,3].
Persistence of the cyst implies an ongoing communication
with the disrupted pancreatic duct [3]. The patient's
chronic abdominal pain was likely due, at least in part, to
the development of a pseudocyst. Pseudocysts seem more
likely to persist in patients who continue to drink alcohol
[2,4]. Their persistence in narcotic users is less appreci-
ated.
Pancreatic pseudocyst management has tended towards
watchful waiting [3,8,9]. The first planned operation of a
pancreatic cyst was in 1822 in Prague by Carl Gussen-
bauer [1]. He palpated an 8.5 × 22 cm swelling in the epi-
gastrium of a 40 year old man who recently drank 7 liters
of beer. An abdominal incision was used to drain 1900 cc
of grayish, black fluid. The patient improved but later
developed an external pancreatic fistula. He was dis-
charged against medical advice on post-operative day 84.
Back then, pancreatic pseudocysts were diagnosed by
physical exam [1]. Consequently, cysts had to be quite
large before they could be found. Even with the help of an
upper GI series, introduced in 1910 [10], any cysts discov-
ered were big, and spontaneous resolution was thought to
be rare (less than 10%). As a result, most that were discov-
ered were drained [1].
Two conservative trends followed and each was driven, in
part, by advances in imaging [3]. The first trend occurred
one hundred and fifty years after Gussenbauer's partial
success. In 1979, Bradley and colleagues followed the nat-
ural history of pseudocysts by ultrasonography. They
noted cysts less then 6 cm had a 40% spontaneous resolu-
tion rate and a very low complication rate (20%). Pseudo-
cysts present more than 6 weeks, however, almost never
resolved and had a very high complication rate (46%).
Consequently there was a strong trend to observe smaller,
younger pseudocysts [8]. Surgical drainage was reserved
for cysts 'greater than 6 cm or present for more than 6
weeks.'
The second and latest trend followed a study using com-
puted tomography (CT) imaging [9]. In the late 1980's,
Yeo et al observed the natural history of pseudocysts by
CT. The '6 cm or 6 week' paradigm began to falter. He
noted for, example, 36% of pseudocysts greater than 8 cm
could be managed without surgery. Later, Vitas and Sarr
described 68 patients with pancreatic pseudocysts man-
aged expectantly for as long as 116 months (mean 51
months). Serious complications were seen in 9% of this
expectant group compared to 10% of patients who had
elective operations in the primary treatment group [4].
Now there is no longer a cut and dried quantitative policy
CT of the abdomen 7 months later after insertion of the  transgasticstent Figure 3
CT of the abdomen 7 months later after insertion of 
the transgasticstent. The pseudocyst now measures 
just 17 mm in size and the stent is still in place.Cases Journal 2008, 1:219 http://www.casesjournal.com/content/1/1/219
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for surgery. Patients with pseudocysts of any size or dura-
tion can be managed without drainage provided they are
symptom free, and provided the cyst size is stable or
declining [3,11]. Our patient was not symptom free, and
because of his pain, we were unable to observe him for
more than a few weeks.
Most pancreatic pseudocysts are drained internally with
an open surgical approach [11]. Open surgery is indicated
for recurrent pseudocysts, cysts complicated by ductalste-
nosis, and in suspected neoplasm with need for biopsy.
Endoscopic approaches are becoming increasingly popu-
lar but require the cyst be firmly adherent to the gastroin-
testinal tract and bulging into the lumen. For mature cysts,
in experienced hands, endoscopy should be given first
choice. Percutaneous drainage is reserved primarily for
infected cysts and has a 10% risk of a persistent pancreatic
fistula. ERCP is often done first to define pancreatic duct
anatomy and confirm ductal communication with the
cyst [2]. Our patient, as noted, had an endoscopic
approach.
Our patient's care was complicated by narcotic use. I
could find no evidence in the literature for an increased
risk of pseudocyst with prolonged narcotic use. It is at
least theoretically possible. Morphine is known to
increase pancreatic ductal pressure at the sphincter of
Oddi [5,6]. And there are conflicting reports about mor-
phine's effects on pancreatic secretion. Dooley et al dem-
onstrated morphine inhibited pancreatic secretion into
the duodenum [12]. But in an earlier study, Gullo et al
showed morphine actually increased volume of water and
electrolyte secretion from the pancreas [7]. The discrep-
ancy could be explained by their respective methods.
Dooley at al measured duodenal aspirates while Gullo et
al inserted a polyethylene tube directly into Wirsung's
canal. It is possible that by simultaneously increasing
sphincter of Oddi pressure, morphine decreases pancre-
atic secretion if measured distally to the sphincter (in the
duodenum) but in fact increases intrapancreatic secretion
over all. Increasing both ductal pressure and intra-pancre-
atic secretion could favor development of a pseudocyst.
Interesting, tramadol, which was shown to decrease
sphincter of Oddi pressure, has been rated as a better anal-
gesic for chronic pancreatits pain compared to morphine
[13].
Conclusion
Pancreatic pseudocysts should be considered in the differ-
ential of any patient with chronic abdominal pain, espe-
cially if he or she has a history of chronic pancreatitis.
Their unique physiology, evolution of management, and
potential relation to narcotic use make them worthy of
review. Further clarifying any potential role of narcotics in
pancreatic pseudocyst development would be important.
Many patients manage the pain of chronic pancreatitis
with narcotics.
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